Systemic therapy for advanced hepatocellular carcinoma (HCC) includes multi‐kinase inhibitors with anti‐vascular endothelial growth factor (VEGF) activity and anti‐VEGF monoclonal antibodies in combination with immune checkpoint inhibitors. This study aimed… Click to show full abstract
Systemic therapy for advanced hepatocellular carcinoma (HCC) includes multi‐kinase inhibitors with anti‐vascular endothelial growth factor (VEGF) activity and anti‐VEGF monoclonal antibodies in combination with immune checkpoint inhibitors. This study aimed to investigate and compare the chronological changes in liver volume between patients who received atezolizumab plus bevacizumab (Atezo/Bev) and those who received lenvatinib.
Keywords:
anti angiogenic;
agents advanced;
angiogenic agents;
advanced hepatocellular;
hepatocellular carcinoma
Journal Title: Cancer Medicine
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Medicine
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!